Gastrointestinal Cancers Symposium

GI 2018 Daily News Thursday

Issue link: http://read.uberflip.com/i/926712

Contents of this Issue

Navigation

Page 0 of 23

Symposium Faculty Provide Global Perspectives on GI Cancers T he challenges associated with treating gastroin- testinal (GI) cancers are not isolated to the Unit- ed States. For that reason, the 2018 GI Cancers Symposium will highlight global perspec- tives on gastrointestinal can- cers with its theme, "Multidis- ciplinary Care: Local Practice, Global Outcomes." "So many GI cancers are glob- al diseases, and many have a higher incidence and mortality in countries outside of North America," Steering Committee Chair Laura A. Dawson, MD, FRCPC, of Princess Margaret Cancer Centre, Toronto, said. For example, stomach can- cer is the third leading cause of cancer death worldwide. More than 70% of cases occur in de- veloping countries, and 50% of cases occur in East Asia. 1 "With this Symposium, we wanted to highlight variations in practice and outcomes around the world," Dr. Dawson said. The GI Cancers Symposium is unique because of its high inter- national attendance, Program Committee Chair Karyn Good- man, MD, MS, of the University of Colorado School of Medi- cine, said. Out of last year's ap- proximately 3,270 professional attendees, more than half were from outside the United States. This global representation is important because many of the advances in the treatment of GI cancers in recent years have been through large clinical trials conducted outside of the United States. "We want to be sure that we are including speakers and participants from all over the world because they bring such a widespread knowledge about the management of these cancers," Dr. Goodman said. Theme Integration When developing this year's program, committee members were asked to consider the glob- al theme in every subspecialty stream. For example, "General Session 2: Global Outlook on Gastric Cancer," on January 18, will include discussion on gastric cancer surveillance and manage- ment from speakers represent- ing European, South Ameri- can, and Asian perspectives. "The incidence and mor- tality of gastric cancer varies enormously among different areas of the planet, and they are particularly high in low- income countries or low socio- economic-income groups in high-income regions," Session Chair Ulysses Ribeiro, MD, PhD, of the University of São Paulo, Brazil, said. "The differences that may exist in various coun- tries and regions may help us to better understand and manage this devastating disease." Lenvatinib for HCC Treatment A fsaneh Barzi, MD, and Vincent Chung, MD, FACP, answer a question posed by an attendee during a Best of ASCO ® Meet- ing. Dr. Barzi is an assistant pro- fessor of medicine and medical director of quality cancer care with the Norris Comprehensive Cancer Center, Keck School of Medicine, of the University of Southern California. Dr. Chung is an associate clinical professor with the City of Hope. Question: What role will lenvatinib play in the landscape of hepatocellular carcinoma treatment? Answer: Hepatocellular carci- noma (HCC) is the third lead- ing cause of cancer-related deaths in the world. 1 Yet, limit- ed progress has been made with systemic therapies. For the last Clinical Corner The Role of Adjuvant Chemotherapy Following Neoadjuvant Treatment in Rectal Cancer Daphna Y. Spiegel, MD, MS; Hope Uronis, MD, MHS; Brian G. Czito, MD; Christopher G. Willett, MD; and Manisha Palta, MD A pproximately 39,000 people are diagnosed with rectal adenocarcinoma in the United States annually. 1 Adjuvant chemotherapy following chemoradiation and total meso- rectal excision (TME) for locoregionally advanced rectal cancer has become a standard of care in the United States despite limited data. Historic Data The role of adjuvant chemotherapy in rectal cancer was first eval- uated in the NSABP R-01 trial in 555 patients with Dukes' B and C disease. Patients were randomly assigned to adjuvant chemothera- py with 5-fluorouracil (5-FU), semustine, and vincristine; adjuvant radiotherapy; or no further treatment. Both overall survival (OS) and disease-specific survival benefits were seen with the addition of chemotherapy compared to surgery alone (p = 0.05 and p = 0.006, respectively) and established adjuvant chemotherapy following rectal cancer resection as a standard of care. 2 Despite wide adoption of adjuvant chemotherapy following publication, the analysis did not account for meaningful differences in baseline patient charac- teristics, as healthier patients were more likely to receive adjuvant chemotherapy and expected to live longer regardless of additional therapy. Furthermore, although this outcome was meaningful dur- ing this era, this study was conducted prior to routine use of neoad- juvant therapy and the TME technique. Attendee Tip of the Day New Rapid-Fire Abstract Sessions provide additional opportunities to hear the latest research. See Global Theme, Page 3 See Role of Adjuvant Chemotherapy, Page 4 T A R G E T I N G C A N C E R C A R E India Responds to Its Growing Cancer Crisis 3 Why I Attend: A Community Oncologist's Perspective 5 ASTRO Launches Patient Stories Portal 5 Treating HCC in 2018 12 Ancillary Educational Events 14 SSO Launches ExpertEd@SSO 14 Maximize Your Time at the Poster Sessions 15 Symposium Essentials 15, 22, 25 Earn MOC Points 15 Minimally Invasive Surgery for Gastric Cancer: Is There a Benefit? 16 Attend the International Symposium on Regional Cancer Therapies 21 Restaurant Recommendations 21 Attend SSO 2018 22 HIPEC to Be Debated at Breakout Session 22 ASCO's QOPI ® Recognizes Practices in Spain 23 CancerLinQ Update 25 Aspirin Use and Colorectal Cancer Survival 25 INSIDE DAILY NEWS THURSDAY · JA N UA RY 1 8 · SA N F RA N C I SCO Gastrointestinal Cancers Symposium 2018 • Abstracts grouped thematically. • Includes 5-minute abstract presentations with dedicated question and answer panels. • Not ticketed, but seating is limited. • Times and locations available on the iPlanner and Program. See HCC Treatment, Page 11 Dr. Laura A. Dawson Dr. Karyn Goodman Dr. Ulysses Ribeiro Dr. Rodrigo Jover

Articles in this issue

view archives of Gastrointestinal Cancers Symposium - GI 2018 Daily News Thursday